Compare CCO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | OCS |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2005 | N/A |
| Metric | CCO | OCS |
|---|---|---|
| Price | $2.08 | $23.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $2.10 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 2.6M | 119.4K |
| Earning Date | 02-23-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,569,344,000.00 | $991,999.00 |
| Revenue This Year | $6.76 | $14.53 |
| Revenue Next Year | $4.42 | $691.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.21 | N/A |
| 52 Week Low | $0.81 | $14.00 |
| 52 Week High | $2.26 | $23.08 |
| Indicator | CCO | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 73.77 |
| Support Level | $2.04 | $19.70 |
| Resistance Level | $2.17 | $22.14 |
| Average True Range (ATR) | 0.09 | 0.89 |
| MACD | -0.02 | 0.28 |
| Stochastic Oscillator | 20.00 | 94.06 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.